# SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

> **NCT00096499** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** ispinesib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00096499
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-04
- **Primary completion:** 2007-01
- **Final completion:** —
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00096499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00096499, "SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00096499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*